Cystic Fibrosis Clinical Trial
Official title:
Effects of Inspiratory Muscle Training in Individuals Who Have Cystic Fibrosis
Verified date | April 2020 |
Source | Universidade Federal do Rio Grande do Norte |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Cystic fibrosis is a genetic disease that affects some organs of the human body. Among them, the lungs tend to be the most affected due to the accumulation of mucus in the airways, which in addition to avoiding the passage of air, favors pulmonary infections. With the evolution of the condition, secondary complications arise, such as postural changes, decreased respiratory muscle strength, decreased functional capacity and, consequently, quality of life. Therefore, respiratory muscle training may be an intervention that improves the respiratory condition of these individuals, allowing an improvement in the quality of life and may delay the evolution of respiratory symptoms. Thus, this study aims to investigate a home protocol of respiratory muscle training on respiratory muscle strength, lung function, quality of life, posture and functional capacity in adolescents and adults with cystic fibrosis. The researchers believe that the training can cause an improvement in the studied variables, and can be inserted in the usual treatment of these patients.
Status | Completed |
Enrollment | 10 |
Est. completion date | January 31, 2020 |
Est. primary completion date | October 18, 2019 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 14 Years to 25 Years |
Eligibility |
Inclusion Criteria: - Diagnosis of cystic fibrosis, confirmed by the sweat test; - 14 - 25 years; - Clinical stability; - Absence of bacterial colonization for 4 weeks; - Both sexes; Exclusion Criteria: - Inability to perform the protocol established by the study; - Present any intercurrence during data collection; - Being unable to understand and / or perform procedures. - Colonization during study participation; - Patient hospitalization due to worsening of the clinical picture. |
Country | Name | City | State |
---|---|---|---|
Brazil | Universidade Federal do Rio Grande do Norte | Natal | Rio Grande Do Norte |
Lead Sponsor | Collaborator |
---|---|
Universidade Federal do Rio Grande do Norte |
Brazil,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change from baseline Posture at 4 weeks | Inclinometer Danoplus® | Baseline and after 4 weeks of training | |
Primary | Change from baseline Health-related quality of life at 4 weeks | Health-related quality of life questionnaire (HRQoL) | Baseline and after 4 weeks of training | |
Secondary | Change from baseline Respiratory muscle strength at 4 weeks | MVD300® | Baseline and after 4 weeks of training | |
Secondary | Change from baseline Pulmonary function at 4 weeks | Spirometry test using Koko® device | Baseline and after 4 weeks of training | |
Secondary | Change from baseline Functional capacity at 4 weeks | three-minute step test | Baseline and after 4 weeks of training |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04696198 -
Thoracic Mobility in Cystic Fibrosis Care
|
N/A | |
Completed |
NCT00803205 -
Study of Ataluren (PTC124™) in Cystic Fibrosis
|
Phase 3 | |
Terminated |
NCT04921332 -
Bright Light Therapy for Depression Symptoms in Adults With Cystic Fibrosis (CF) and COPD
|
N/A | |
Completed |
NCT03601637 -
Safety and Pharmacokinetic Study of Lumacaftor/Ivacaftor in Participants 1 to Less Than 2 Years of Age With Cystic Fibrosis, Homozygous for F508del
|
Phase 3 | |
Terminated |
NCT02769637 -
Effect of Acid Blockade on Microbiota and Inflammation in Cystic Fibrosis (CF)
|
||
Recruiting |
NCT06032273 -
Lung Transplant READY CF 2: CARING CF Ancillary RCT
|
N/A | |
Recruiting |
NCT06012084 -
The Development and Evaluation of iCF-PWR for Healthy Siblings of Individuals With Cystic Fibrosis
|
N/A | |
Recruiting |
NCT06030206 -
Lung Transplant READY CF 2: A Multi-site RCT
|
N/A | |
Recruiting |
NCT05392855 -
Symptom Based Performance of Airway Clearance After Starting Highly Effective Modulators for Cystic Fibrosis (SPACE-CF)
|
N/A | |
Recruiting |
NCT06088485 -
The Effect of Bone Mineral Density in Patients With Adult Cystic Fibrosis
|
||
Recruiting |
NCT04039087 -
Sildenafil Exercise: Role of PDE5 Inhibition
|
Phase 2/Phase 3 | |
Recruiting |
NCT04056702 -
Impact of Triple Combination CFTR Therapy on Sinus Disease.
|
||
Completed |
NCT04038710 -
Clinical Outcomes of Triple Combination Therapy in Severe Cystic Fibrosis Disease.
|
||
Completed |
NCT04058548 -
Clinical Utility of the 1-minute Sit to Stand Test as a Measure of Submaximal Exercise Tolerance in Patients With Cystic Fibrosis During Acute Pulmonary Exacerbation
|
N/A | |
Completed |
NCT03637504 -
Feasibility of a Mobile Medication Plan Application in CF Patient Care
|
N/A | |
Recruiting |
NCT03506061 -
Trikafta in Cystic Fibrosis Patients
|
Phase 2 | |
Completed |
NCT03566550 -
Gut Imaging for Function & Transit in Cystic Fibrosis Study 1
|
||
Recruiting |
NCT04828382 -
Prospective Study of Pregnancy in Women With Cystic Fibrosis
|
||
Completed |
NCT04568980 -
Assessment of Contraceptive Safety and Effectiveness in Cystic Fibrosis
|
||
Recruiting |
NCT04010253 -
Impact of Bronchial Drainage Technique by the Medical Device Simeox® on Respiratory Function and Symptoms in Adult Patients With Cystic Fibrosis
|
N/A |